A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-Positive Breast Cancer Patients

Targeted axillary dissection (TAD) involves targeted lymph node biopsy and SLNB. SenTa study is a prospective registry study conducted across 50 centres which aims to investigate the feasibility and accuracy of TAD in patients undergoing neoadjuvant systemic therapy (NST). Patients had clip inserted into the biopsy-confirmed positive lymph nodes. After NST, the clipped node was resected in 329 of 423 patients (77.8%). TAD was successful in 199 of 229 patients (detection rate of 86.9%) with sentinel lymph node and targeted lymph node identical in 129 patients (64.8%). The FNR was 4.3% for TAD followed by ALND.  

Classifications: Breast & Oncoplastic Surgery

Keywords: Axilla Trials